Latest TroVax Stories
CALGARY, April 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma. The pivotal Phase III study will evaluate as the primary endpoint...
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.
OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...
CALGARY, Feb. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) announced today that enrollment has been completed in a U.K.
ROCKVILLE, Md., Feb. 4, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor.
BRIDGEWATER, N.J., Jan.
WORCESTER, Mass., Jan. 25, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc.
Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN Calgary, Alberta (Vocus/PRWEB) January 18, 2011 Colorectal cancer is the third leading cause of cancer death among both men and women in the US.
Quality of life measures seem to be most useful for clinical decision-making in trials where quality of life is the primary outcome, according to a new study.
- A volcanic mudflow.